Consumer Reports Negative on Teva Pharma (TEVA), Mylan (MYL) Deal
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $40.06 +2.77%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.1%
EPS Growth %: -11.5%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.1%
EPS Growth %: -11.5%
Join SI Premium – FREE
Consumer Reports is out negative on the potential deal between Mylan (Nasdaq: MYL) and Teva Pharma (NYSE: TEVA).
In part, the report notes that the deal could hand consumers higher prices for generic and specialty drugs.
Teva and Mylan are both trading at or near session lows on Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paramount settles with U.S. states over Warner Bros. merger
- newcleo to begin trading on Nasdaq after $247M SPAC deal closes
- Artemis Gold to acquire Vista Gold in US$427M all-share deal
Create E-mail Alert Related Categories
Insiders' Blog, Mergers and AcquisitionsRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
